Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
NO_LONGER_AVAILABLE
Conditions studied: Non-small Cell Lung Cancer (NSCLC)
In brief
Novartis-sponsored, open-label, multi-center, interventional ETP to provide LDK378 to patients with ALK (+)NSCLC, who have been pre-treated with an ALK inhibitor; except in countries where ALK inhibitors are not approved or available. The protocol will further evaluate the safety of LDK378 in patients with ALK(+) NSCLC.
Key facts
- Study ID
- NCT01947608
- Run by
- Novartis Pharmaceuticals
- Last updated by the study team
- 2020-11-03
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Ironwood Cancer and Research Centers — Chandler, Arizona, United States
- Banner MDACC — Gilbert, Arizona, United States
- Western Regional Medical Center, Inc. — Goodyear, Arizona, United States
- Highlands Oncology Group — Fayetteville, Arkansas, United States
- City of Hope National Medical Center — Duarte, California, United States
- Moores UCSD Cancer Center — La Jolla, California, United States
- St Joseph Heritage Healthcare — Santa Rosa, California, United States
- Stanford University — Stanford, California, United States
- Eastern Connecticut Hematology & Oncology Associates — Norwich, Connecticut, United States
- Advanced Medical Specialties — Miami, Florida, United States
- Peachtree Hematology/Oncology Consultants — Atlanta, Georgia, United States
- Emory University School of Medicine/Winship Cancer Institute — Atlanta, Georgia, United States
- Lurie Children's Hospital of Chicago — Chicago, Illinois, United States
- Indiana University Health Goshen Center for Cancer — Goshen, Indiana, United States
- Johns Hopkins Bayview Hospital — Baltimore, Maryland, United States
- Maryland Oncology Hematology, P.A. — Rockville, Maryland, United States
- Massachusetts General Hospital Mass General — Boston, Massachusetts, United States
- Karmanos Cancer Institute — Detroit, Michigan, United States
- Jackson Oncology Associates — Jackson, Mississippi, United States
- Nebraska Cancer Specialist/Missouri Valley Cancer Consortium — Omaha, Nebraska, United States
- Hackensack University Medical Center — Hackensack, New Jersey, United States
- Mercy Clinic Oklahoma Communities Mercy Oncology — Oklahoma City, Oklahoma, United States
- Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
- Tennessee Cancer Specialists — Knoxville, Tennessee, United States
- University of Utah / Huntsman Cancer Institute — Salt Lake City, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.